PMID- 32501985
OWN - NLM
STAT- MEDLINE
DCOM- 20200630
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 23
DP  - 2020 Jun 5
TI  - Influences of different dose of tirofiban for acute ST elevation myocardial 
      infarction patients underwent percutaneous coronary intervention.
PG  - e20402
LID - 10.1097/MD.0000000000020402 [doi]
LID - e20402
AB  - Tirofiban is widely used in patients with acute ST elevation myocardial 
      infarction (STEMI) underwent percutaneous coronary intervention (PCI). This drug 
      can efficiently improve myocardial perfusion and cardiac function, but its dose 
      still remains controversial. We here investigated the effects of different dose 
      of tirofiban on myocardial reperfusion and heart function in patients with STEMI. 
      A total of 312 STEMI patients who underwent PCI in our hospital from March 2017 
      to March 2018 were enrolled and randomly divided into control group (75 cases, 
      0 mug/kg), low-dose group (79 cases, 5 mug/kg), medium-dose group (81 cases, 
      10 mug/kg) and high-dose group (77 cases, 20 mug/kg). The infarction-targeted 
      artery flow grade evaluated by thrombolysis in myocardial infarction (TIMI), 
      corrected TIMI frame count (CTFC) and sum-ST-segment resolution were recorded. At 
      Day 7 and Day 30 after PCI, the left ventricular ejection fraction (LVEF), left 
      ventricular end diastolic diameter, left ventricular end systolic diameter, major 
      adverse cardiovascular events and the hemorrhage and thrombocytopenia were also 
      evaluated. After PCI, the rate of TIMI grade 3, CTFC and incidence of 
      sum-ST-segment resolution > 50% of high-dose group were significantly higher than 
      those of control group, low-dose group and medium-dose group (P < .05), and the 
      CTFC of medium -dose group were significantly higher than that of control group, 
      low-dose group (P < .05). Moreover, the LVEF, left ventricular end diastolic 
      diameter and left ventricular end systolic diameter of high-dose group were 
      significantly improved than those of other groups, and the LVEF of medium-dose 
      group was significantly superior to that of low-dose group (P < .05). However, 
      the incidence of major adverse cardiac events in high-dose group was 
      significantly decreased, while the hemorrhage and incidence of thrombocytopenia 
      of high-dose group were significantly higher than those of other 3 groups 
      (P < .05). The tirofiban can effectively alleviate the myocardial 
      ischemia-reperfusion injury and promote the recovery of cardiac function in STEMI 
      patients underwent PCI. Although the high-dose can enhance the clinical effects, 
      it also increased the hemorrhagic risk. Therefore, the rational dosage 
      application of tirofiban become much indispensable in view of patient's 
      conditions and hemorrhagic risk, and a medium dose of 10 mug/kg may be appropriate 
      for patients without high hemorrhagic risk.
FAU - Wang, Haixia
AU  - Wang H
AD  - Department Pharmacy, the Second Clinical Hospital of Shanxi Medical University, 
      Taiyuan, Shanxi.
FAU - Feng, Meiqin
AU  - Feng M
AD  - AstraZeneca (Wuxi) trading co. LTD, Wuxi, Jiangsu, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - GGX234SI5H (Tirofiban)
SB  - IM
MH  - Aged
MH  - Chi-Square Distribution
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/*methods/standards/statistics & numerical data
MH  - Platelet Aggregation Inhibitors/administration & dosage/standards/therapeutic use
MH  - ST Elevation Myocardial Infarction/*drug therapy/epidemiology
MH  - Stroke Volume/drug effects
MH  - Tirofiban/*administration & dosage/*standards/therapeutic use
MH  - Treatment Outcome
PMC - PMC7306376
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/06/06 06:00
MHDA- 2020/07/01 06:00
PMCR- 2020/06/05
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2020/06/05 00:00 [pmc-release]
AID - 00005792-202006050-00023 [pii]
AID - MD-D-20-00967 [pii]
AID - 10.1097/MD.0000000000020402 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 5;99(23):e20402. doi: 10.1097/MD.0000000000020402.